Tumour microvessel density as predictor of chemotherapy response in breast cancer patients

被引:20
作者
Tynninen, O [1 ]
Sjöström, J
von Boguslawski, K
Bengtsson, NO
Heikkilä, R
Malmström, P
Ostenstad, B
Wist, E
Valvere, V
Saksela, E
Paavonen, T
Blomqvist, C
机构
[1] Univ Helsinki, Cent Hosp, Div Pathol, HUCH Lab Diagnost, Helsinki 00029, Finland
[2] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki 00029, Finland
[3] Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland
[4] Umea Univ Hosp, S-90185 Umea, Sweden
[5] Cent Hosp Rogaland, N-4011 Stavanger, Norway
[6] Univ Lund Hosp, S-21185 Lund, Sweden
[7] Ulleval Hosp, N-0407 Oslo, Norway
[8] Univ Tromso Hosp, N-9012 Tromso, Norway
[9] Estonian Canc Ctr, EE-00106 Tallinn, Estonia
[10] Univ Uppsala Hosp, S-75185 Uppsala, Sweden
关键词
microvessel density; chemotherapy; metastatic breast cancer; predictive factor;
D O I
10.1038/sj.bjc.6600325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to evaluate the predictive value of intratumoural microvessel density in breast cancer. We studied immunohistochemically primary tumours of 104 patients with metastasised breast cancer who took part in a randomised multicentre trial comparing docetaxel to sequential methotrexate and 5-fluorouracil. Vessels were highlighted with factor VIII staining and counted microscopically. Microvessel density was compared with clinical response to chemotherapy and patient survival. The microvessel density of the primary tumour was not significantly associated with patient's response to chemotherapy, time to progression or overall survival in the whole patient population or in the docetaxel or methotrexate and 5-fluorouracil groups. However, disease-free survival was longer in patients with low microvessel density (P=0.01). These findings suggest that microvessel density of the primary tumour cannot be used as a predictive marker for chemotherapy response in advanced breast cancer. (C) 2002 Cancer Research UK.
引用
收藏
页码:1905 / 1908
页数:4
相关论文
共 36 条
[1]   TUMOR ANGIOGENESIS AS A PROGNOSTIC ASSAY FOR INVASIVE DUCTAL BREAST-CARCINOMA [J].
AXELSSON, K ;
LJUNG, BME ;
MOORE, DH ;
THOR, AD ;
CHEW, KL ;
EDGERTON, SM ;
SMITH, HS ;
MAYALL, BH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (13) :997-1008
[2]  
Belotti D, 1996, CLIN CANCER RES, V2, P1843
[3]   Development of inflammatory angiogenesis by local stimulation of Fas in vivo [J].
Biancone, L ;
DeMartino, A ;
Orlandi, V ;
Conaldi, PG ;
Toniolo, A ;
Camussi, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :147-152
[4]   MICROVESSEL QUANTITATION AND PROGNOSIS IN INVASIVE BREAST-CARCINOMA [J].
BOSARI, S ;
LEE, AKC ;
DELELLIS, RA ;
WILEY, BD ;
HEATLEY, GJ ;
SILVERMAN, ML .
HUMAN PATHOLOGY, 1992, 23 (07) :755-761
[5]  
CORLE DK, 1984, CANCER, V54, P1554, DOI 10.1002/1097-0142(19841015)54:8<1554::AID-CNCR2820540815>3.0.CO
[6]  
2-4
[7]   THE INFLUENCE OF ANGIOGENESIS RESEARCH ON MANAGEMENT OF PATIENTS WITH BREAST-CANCER [J].
FOLKMAN, J .
BREAST CANCER RESEARCH AND TREATMENT, 1995, 36 (02) :109-118
[8]  
Gasparini G, 1996, CLIN CANCER RES, V2, P1191
[9]   TUMOR MICROVESSEL DENSITY, P53 EXPRESSION, TUMOR SIZE, AND PERITUMORAL LYMPHATIC VESSEL INVASION ARE RELEVANT PROGNOSTIC MARKERS IN NODE-NEGATIVE BREAST-CARCINOMA [J].
GASPARINI, G ;
WEIDNER, N ;
BEVILACQUA, P ;
MALUTA, S ;
DALLAPALMA, P ;
CAFFO, O ;
BARBARESCHI, M ;
BORACCHI, P ;
MARUBINI, E ;
POZZA, F .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :454-466
[10]  
Hansen S, 2000, CLIN CANCER RES, V6, P139